Description

Based in Dublin, Ireland, Ovoca Bio plc is a biopharmaceutical firm specializing in clinical-stage research and development. Founded in 1985, the company is dedicated to creating and commercializing novel therapeutic solutions for various female sexual dysfunctions. Its flagship product candidate, BP-101, is being developed as a medical intervention for premenopausal women experiencing hypoactive sexual desire disorder. BP-101 is currently in Phase II clinical trials across Australia and New Zealand, with Phase III trials concurrently underway in Russia. Additionally, the company maintains involvement in mineral exploration activities and provides support services. Originally incorporated as Ovoca Gold plc, the company rebranded to Ovoca Bio plc in July 2018.